The 10-day moving average for ICUI crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ICUI as a result. In 60 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for ICUI just turned positive on November 04, 2026. Looking at past instances where ICUI's MACD turned positive, the stock continued to rise in 32 of 51 cases over the following month. The odds of a continued upward trend are 63%.
ICUI moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICUI advanced for three days, in 189 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 154 of 204 cases where ICUI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
The 10-day RSI Indicator for ICUI moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 16 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 59%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICUI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
ICUI broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ICUI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.000) is normal, around the industry mean (4.964). ICUI has a moderately high P/E Ratio (143.425) as compared to the industry average of (40.591). Projected Growth (PEG Ratio) (0.081) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.808) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICUI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The 10-day moving average for OPK crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on OPK as a result. In 74 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for OPK just turned positive on October 19, 2026. Looking at past instances where OPK's MACD turned positive, the stock continued to rise in 29 of 40 cases over the following month. The odds of a continued upward trend are 73%.
OPK moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where OPK advanced for three days, in 159 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The Aroon Indicator entered an Uptrend today. In 123 of 154 cases where OPK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
The 10-day RSI Indicator for OPK moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 24 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 58 cases where OPK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
OPK broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.090) is normal, around the industry mean (67.298). P/E Ratio (-24.714) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.134) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. OPK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
ICUI | OPK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 31 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 89 | 92 | |
PRICE GROWTH RATING 1..100 | 39 | 36 | |
P/E GROWTH RATING 1..100 | 97 | 88 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OPK's Valuation (31) in the Biotechnology industry is somewhat better than the same rating for ICUI (87) in the Medical Specialties industry. This means that OPK’s stock grew somewhat faster than ICUI’s over the last 12 months.
OPK's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ICUI (100) in the Medical Specialties industry. This means that OPK’s stock grew similarly to ICUI’s over the last 12 months.
ICUI's SMR Rating (89) in the Medical Specialties industry is in the same range as OPK (92) in the Biotechnology industry. This means that ICUI’s stock grew similarly to OPK’s over the last 12 months.
OPK's Price Growth Rating (36) in the Biotechnology industry is in the same range as ICUI (39) in the Medical Specialties industry. This means that OPK’s stock grew similarly to ICUI’s over the last 12 months.
OPK's P/E Growth Rating (88) in the Biotechnology industry is in the same range as ICUI (97) in the Medical Specialties industry. This means that OPK’s stock grew similarly to ICUI’s over the last 12 months.
| ICUI | OPK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 59% | 1 day ago 80% |
| Stochastic ODDS (%) | 1 day ago 68% | 1 day ago 84% |
| Momentum ODDS (%) | 1 day ago 65% | 1 day ago 80% |
| MACD ODDS (%) | 1 day ago 63% | 1 day ago 73% |
| TrendWeek ODDS (%) | 1 day ago 68% | 1 day ago 80% |
| TrendMonth ODDS (%) | 1 day ago 73% | 1 day ago 75% |
| Advances ODDS (%) | 3 days ago 68% | 15 days ago 74% |
| Declines ODDS (%) | 10 days ago 71% | 4 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 74% | 1 day ago 79% |
| Aroon ODDS (%) | 1 day ago 75% | 1 day ago 80% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ICUI’s FA Score shows that 0 FA rating(s) are green while OPK’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ICUI’s TA Score shows that 6 TA indicator(s) are bullish while OPK’s TA Score has 6 bullish TA indicator(s).
ICUI (@Pharmaceuticals: Other) experienced а +3.27% price change this week, while OPK (@Medical Specialties) price change was -3.39% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.07%. For the same industry, the average monthly price growth was +6.43%, and the average quarterly price growth was +22.77%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.83%. For the same industry, the average monthly price growth was -5.05%, and the average quarterly price growth was +38.36%.
ICUI is expected to report earnings on Mar 03, 2027.
OPK is expected to report earnings on Mar 04, 2027.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-4.83% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, ICUI has been loosely correlated with CLPT. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ICUI jumps, then CLPT could also see price increases.
| Ticker / NAME | Correlation To ICUI | 1D Price Change % | ||
|---|---|---|---|---|
| ICUI | 100% | -2.11% | ||
| CLPT - ICUI | 57% Loosely correlated | +4.56% | ||
| ALGN - ICUI | 55% Loosely correlated | -1.25% | ||
| MMSI - ICUI | 52% Loosely correlated | +0.30% | ||
| A - ICUI | 50% Loosely correlated | -0.52% | ||
| COO - ICUI | 49% Loosely correlated | -1.01% | ||
More | ||||
A.I.dvisor indicates that over the last year, OPK has been loosely correlated with ICUI. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if OPK jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To OPK | 1D Price Change % | ||
|---|---|---|---|---|
| OPK | 100% | N/A | ||
| ICUI - OPK | 41% Loosely correlated | -2.11% | ||
| CLPT - OPK | 39% Loosely correlated | +4.56% | ||
| CRL - OPK | 36% Loosely correlated | -0.90% | ||
| IQV - OPK | 36% Loosely correlated | -0.23% | ||
| UTMD - OPK | 36% Loosely correlated | +0.23% | ||
More | ||||